INBS INTELLIGENT BIO SOLUTIONS INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1725430 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY57.2%
TTM net income YoY-11.4%
TTM EPS YoY74.6%
Revenue 3-yr CAGR27.6%
Net income 3-yr CAGR—
Margins
Gross margin50.9%
Operating margin-272.2%
Net margin-269.3%
FCF margin—
EBITDA margin-246.5%
Returns
ROE-216.1%
ROA-102.3%
ROIC (approx.)-534.9%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets46.0%
Debt / equity0.00x
Current ratio1.98x
Interest coverage-187.68x
Cash quality & payout
Operating cash flow / net income0.98x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $4.22M | $3.05M |
| Cost of revenue | $2.17M | $1.81M |
| Gross profit | $2.05M | $1.25M |
| SG&A expense | $10.50M | $8.92M |
| Operating income | -$12.61M | -$10.68M |
| Interest expense | $10,736 | $26,339 |
| Net income | -$12.43M | -$10.57M |
| EBITDA | -$11.44M | -$9.47M |
| EPS (basic) | -8.44 | -20.04 |
| EPS (diluted) | -8.44 | -20.04 |
| Weighted avg. shares (diluted) | 1.47M | 527,364 |
| Balance sheet | ||
| Cash & equivalents | $3.99M | $1.02M |
| Receivables | $848,464 | $594,614 |
| Inventory | $418,577 | $635,215 |
| Current assets | $7.10M | $4.14M |
| PP&E, net | $294,399 | $251,325 |
| Intangibles | $2.80M | $3.79M |
| Total assets | $11.94M | $8.25M |
| Current liabilities | $4.93M | $5.35M |
| Total liabilities | $6.65M | $5.44M |
| Shareholders' equity | $5.51M | $3.00M |
| Shares outstanding | 2.91M | 732,327 |
| Cash flow statement | ||
| Operating cash flow | -$11.93M | -$9.68M |
| Capital expenditure | $125,731 | $231,838 |
| Free cash flow | -$12.05M | -$9.91M |
| Investing cash flow | -$85,573 | -$231,838 |
| Financing cash flow | $14.98M | $4.60M |
| Depreciation & amortization | $1.16M | $1.21M |
| Stock-based compensation | $195,208 | $238,045 |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.